Flora Peyvandi
#117,837
Most Influential Person Now
Researcher
Flora Peyvandi's AcademicInfluence.com Rankings
Flora Peyvandicomputer-science Degrees
Computer Science
#4653
World Rank
#4909
Historical Rank
Computational Linguistics
#486
World Rank
#494
Historical Rank
Machine Learning
#980
World Rank
#995
Historical Rank
Artificial Intelligence
#1203
World Rank
#1225
Historical Rank
Download Badge
Computer Science
Flora Peyvandi's Degrees
- PhD Computer Science Stanford University
- Masters Computer Science University of California, Berkeley
- Bachelors Computer Science University of California, Berkeley
Similar Degrees You Can Earn
Why Is Flora Peyvandi Influential?
(Suggest an Edit or Addition)Flora Peyvandi's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Genomewide Association Study of Severe Covid-19 with Respiratory Failure (2020) (1425)
- Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants (2009) (1100)
- Hypercoagulability of COVID‐19 patients in intensive care unit: A report of thromboelastography findings and other parameters of hemostasis (2020) (1079)
- Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease (2011) (894)
- Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies (2012) (692)
- New susceptibility locus for coronary artery disease on chromosome 3q22.3 (2009) (510)
- Recessively inherited coagulation disorders. (2004) (459)
- Mapping the human genetic architecture of COVID-19 (2021) (455)
- Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura (2018) (452)
- Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura. (2016) (396)
- A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A. (2016) (374)
- Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders (2012) (304)
- The past and future of haemophilia: diagnosis, treatments, and its complications (2016) (286)
- The Thrombogram in Rare Inherited Coagulation Disorders: Its Relation to Clinical Bleeding (2002) (285)
- ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. (2005) (275)
- ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission (2008) (240)
- Rare coagulation deficiencies (2002) (238)
- Large-Scale Gene-Centric Analysis Identifies Novel Variants for Coronary Artery Disease (2011) (228)
- No Evidence of Association Between Prothrombotic Gene Polymorphisms and the Development of Acute Myocardial Infarction at a Young Age (2003) (221)
- Rare bleeding disorders: diagnosis and treatment. (2015) (209)
- Clinical phenotypes and factor VII genotype in congenital factor VII deficiency (2005) (204)
- Complement activation in patients with COVID-19: A novel therapeutic target (2020) (201)
- Rare Coagulation Disorders (1999) (197)
- Evaluation and management of postpartum hemorrhage: consensus from an international expert panel (2014) (192)
- Clinical manifestations and complications of childbirth and replacement therapy in 385 Iranian patients with type 3 von Willebrand disease. (2000) (187)
- ADAMTS13 mutations and polymorphisms in congenital thrombotic thrombocytopenic purpura (2010) (170)
- von Willebrand factor cleaving protease (ADAMTS‐13) and ADAMTS‐13 neutralizing autoantibodies in 100 patients with thrombotic thrombocytopenic purpura (2004) (153)
- Role of von Willebrand factor in the haemostasis. (2011) (153)
- Von Willebrand disease and other bleeding disorders in women: consensus on diagnosis and management from an international expert panel. (2009) (151)
- ADAMTS13 activity to antigen ratio in physiological and pathological conditions associated with an increased risk of thrombosis (2007) (136)
- Rare bleeding disorders (2006) (130)
- Genetic diagnosis of haemophilia and other inherited bleeding disorders (2006) (129)
- Fibrinogen replacement therapy for congenital fibrinogen deficiency (2011) (127)
- Smoking and the risk of mortality and vascular and respiratory events in patients undergoing major surgery. (2013) (127)
- Classification of rare bleeding disorders (RBDs) based on the association between coagulant factor activity and clinical bleeding severity (2012) (123)
- The ADAMTS13‐von Willebrand factor axis in COVID‐19 patients (2020) (123)
- Incidence of bleeding symptoms in 100 patients with inherited afibrinogenemia or hypofibrinogenemia (2006) (122)
- Combined deficiency of factor V and factor VIII is due to mutations in either LMAN1 or MCFD2. (2006) (120)
- ISTH guidelines for treatment of thrombotic thrombocytopenic purpura (2020) (118)
- A critical appraisal of one‐stage and chromogenic assays of factor VIII activity (2016) (117)
- CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy (2004) (117)
- The bleeding score predicts clinical outcomes and replacement therapy in adults with von Willebrand disease. (2014) (116)
- Molecular defects in type 3 von Willebrand disease: updated results from 40 multiethnic patients. (2003) (116)
- Introduction. Rare bleeding disorders: general aspects of clinical features, diagnosis, and management. (2009) (115)
- Residual plasmatic activity of ADAMTS13 is correlated with phenotype severity in congenital thrombotic thrombocytopenic purpura. (2012) (108)
- Inhibitor development in haemophilia according to concentrate (2015) (107)
- Evaluation and management of acute menorrhagia in women with and without underlying bleeding disorders: consensus from an international expert panel. (2011) (106)
- Complement activation and endothelial perturbation parallel COVID-19 severity and activity (2020) (105)
- Gene polymorphisms predicting high plasma levels of coagulation and fibrinolysis proteins. A study in centenarians. (1997) (102)
- The Italian AICE-Genetics hemophilia A database: results and correlation with clinical phenotype (2008) (101)
- Factor V deficiency. (2009) (99)
- Molecular analysis of the ERGIC-53 gene in 35 families with combined factor V-factor VIII deficiency. (1999) (99)
- Pattern of symptoms in 93 Iranian patients with severe factor XIII deficiency (2003) (97)
- Factor VIII products and inhibitor development: the SIPPET study (survey of inhibitors in plasma‐product exposed toddlers) (2007) (97)
- Pharmacokinetics and safety of fibrinogen concentrate (2009) (97)
- ADAMTS‐13 assays in thrombotic thrombocytopenic purpura (2010) (96)
- Thrombosis in Inflammatory Bowel Diseases: Role of Inherited Thrombophilia (2005) (94)
- Presentation and pattern of symptoms in 382 patients with Glanzmann thrombasthenia in Iran (2004) (93)
- Clinical manifestations in 28 Italian and Iranian patients with severe factor VII deficiency (1997) (93)
- Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium (2022) (92)
- Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura (2017) (88)
- Molecular Characterisation and Three-Dimensional Structural Analysis of Mutations in 21 Unrelated Families with Inherited Factor VII Deficiency (2000) (83)
- Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis (2021) (83)
- ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura (2020) (82)
- Procoagulant imbalance in patients with non-alcoholic fatty liver disease. (2014) (82)
- Hemostasis and menstruation: appropriate investigation for underlying disorders of hemostasis in women with excessive menstrual bleeding. (2005) (80)
- Congenital afibrinogenemia: mutations leading to premature termination codons in fibrinogen A alpha-chain gene are not associated with the decay of the mutant mRNAs. (2001) (80)
- Anti‐beta 2 glycoprotein I antibodies and the risk of myocardial infarction in young premenopausal women (2007) (80)
- Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: An observational cohort study (2020) (79)
- Novel aspects of factor XIII deficiency (2011) (79)
- Epidemiology and treatment of congenital fibrinogen deficiency. (2012) (79)
- Initial experience from a double‐blind, placebo‐controlled, clinical outcome study of ARC1779 in patients with thrombotic thrombocytopenic purpura (2012) (78)
- Influence of 9p21.3 genetic variants on clinical and angiographic outcomes in early-onset myocardial infarction. (2011) (78)
- ADAMTS‐13 activity and autoantibodies classes and subclasses as prognostic predictors in acquired thrombotic thrombocytopenic purpura (2012) (74)
- Rotational thromboelastography for monitoring of fibrinogen concentrate therapy in fibrinogen deficiency (2008) (74)
- Factor XIII – an under diagnosed deficiency – are we using the right assays? (2010) (73)
- The ABO blood group locus and a chromosome 3 gene cluster associate with SARS-CoV-2 respiratory failure in an Italian-Spanish genome-wide association analysis (2020) (73)
- Molecular Characterization of a Multiethnic Group of 21 Patients with Type 3 von Willebrand Disease (2000) (72)
- Gene mutations and three‐dimensional structural analysis in 13 families with severe factor X deficiency (2002) (71)
- Treatment of rare factor deficiencies other than hemophilia. (2019) (70)
- Variants of OCTN1–2 cation transporter genes are associated with both Crohn's disease and ulcerative colitis (2006) (68)
- Coagulation factor activity and clinical bleeding severity in rare bleeding disorders : results from the European Network of Rare Bleeding Disorders (2007) (67)
- Future of coagulation factor replacement therapy (2013) (66)
- Rare bleeding disorders – bleeding assessment tools, laboratory aspects and phenotype and therapy of FXI deficiency (2014) (65)
- Genotype-phenotype correlation in combined deficiency of factor V and factor VIII. (2008) (64)
- Risk factors for inhibitor development in severe hemophilia a. (2018) (64)
- TTP and ADAMTS13: When Is Testing Appropriate? (2007) (64)
- Rare bleeding disorders (2006) (63)
- Combined FV and FVIII deficiency (2008) (62)
- A comparative evaluation of a new automated assay for von Willebrand factor activity (2013) (62)
- A fatal case of COVID-19 pneumonia occurring in a patient with severe acute ulcerative colitis (2020) (59)
- REDEFINING OUTCOMES IN IMMUNE TTP: AN INTERNATIONAL WORKING GROUP CONSENSUS REPORT. (2021) (59)
- Factor X deficiency. (2009) (59)
- Gynecological and obstetrical manifestations of inherited bleeding disorders in women (2011) (58)
- Patients with localized and disseminated tumors have reduced but measurable levels of ADAMTS-13 (von Willebrand factor cleaving protease). (2003) (58)
- Short-term Exposure to High Altitude Causes Coagulation Activation and Inhibits Fibrinolysis (2002) (58)
- Advances in the treatment of bleeding disorders (2016) (58)
- Second international collaborative study evaluating performance characteristics of methods measuring the von Willebrand factor cleaving protease (ADAMTS‐13) (2008) (58)
- Pregnancy complications and obstetric care in women with inherited bleeding disorders (2013) (58)
- The thrombospondin-1 N700S polymorphism is associated with early myocardial infarction without altering von Willebrand factor multimer size. (2006) (57)
- Hypercoagulability Is a Stronger Risk Factor for Ischaemic Stroke than for Myocardial Infarction: A Systematic Review (2015) (56)
- The association of factor V Leiden with myocardial infarction is replicated in 1880 patients with premature disease (2010) (55)
- Pulmonary embolism in a young pregnant woman with COVID-19 (2020) (54)
- Phenotype‐genotype characterization of 10 families with severe a subunit factor XIII deficiency (2004) (54)
- The effect of emicizumab prophylaxis on health‐related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study (2018) (54)
- Factor V (Arg506⟶ Gln) Mutation in Young Survivors of Myocardial Infarction (1996) (53)
- Rare Bleeding Disorders: Worldwide Efforts for Classification, Diagnosis, and Management (2013) (53)
- Next‐generation sequencing study finds an excess of rare, coding single‐nucleotide variants of ADAMTS13 in patients with deep vein thrombosis (2013) (53)
- Prothrombin 20210G>A is an ancestral prothrombotic mutation that occurred in whites approximately 24,000 years ago. (2006) (53)
- Factor XI deficiency in Iranians: its clinical manifestations in comparison with those of classic hemophilia. (2002) (53)
- Disorders of hemostasis and excessive menstrual bleeding: prevalence and clinical impact. (2005) (53)
- Prothrombin 20210G>A is an ancestral prothrombotic mutation that occurred in whites approximately 24,000 years ago. (2006) (53)
- Role of Chloride Ions in Modulation of the Interaction between von Willebrand Factor and ADAMTS-13* (2005) (52)
- Effects of PCSK9 genetic variants on plasma LDL cholesterol levels and risk of premature myocardial infarction in the Italian population (2010) (52)
- Different clinical severity of first episodes and recurrences of thrombotic thrombocytopenic purpura (2010) (51)
- Phenotype and genotype report on homozygous and heterozygous patients with congenital factor X deficiency (2008) (51)
- Formation of methionine sulfoxide by peroxynitrite at position 1606 of von Willebrand factor inhibits its cleavage by ADAMTS-13: A new prothrombotic mechanism in diseases associated with oxidative stress. (2010) (51)
- Strong association of the APOA5-1131T>C gene variant and early-onset acute myocardial infarction. (2011) (50)
- Genetic architecture of coronary artery disease in the genome-wide era: implications for the emerging "golden dozen" loci. (2009) (50)
- Plasma ADAMTS‐13 levels and the risk of myocardial infarction: an individual patient data meta‐analysis (2015) (50)
- Genetic sequence analysis of inherited bleeding diseases. (2013) (50)
- Ndufc2 Gene Inhibition Is Associated With Mitochondrial Dysfunction and Increased Stroke Susceptibility in an Animal Model of Complex Human Disease (2016) (49)
- Clinical advances in gene therapy updates on clinical trials of gene therapy in haemophilia (2019) (49)
- Rare bleeding disorders (2012) (49)
- Platelet to Lymphocyte Ratio and Neutrophil to Lymphocyte Ratio as Risk Factors for Venous Thrombosis (2017) (48)
- Gynaecological and obstetrical problems in women with different bleeding disorders (2009) (47)
- Prospective study on the behaviour of the metalloprotease ADAMTS13 and of von Willebrand factor after bone marrow transplantation (2006) (47)
- Treatment of rare factor deficiencies in 2016. (2016) (45)
- Effects of CYP2C9 and VKORC1 on INR variations and dose requirements during initial phase of anticoagulant therapy. (2008) (45)
- Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura. (2016) (45)
- Management of pregnancy and delivery in women with inherited bleeding disorders. (2011) (44)
- Hemophilic arthropathy: Current knowledge and future perspectives (2021) (43)
- National and international registries of rare bleeding disorders. (2008) (43)
- Factor XIII deficiency diagnosis: Challenges and tools (2018) (43)
- Tissue plasminogen activator antigen is strongly associated with myocardial infarction in young women (2005) (42)
- Association and Functional Analyses of MEF2A as a Susceptibility Gene for Premature Myocardial Infarction and Coronary Artery Disease (2009) (41)
- Genetic risk stratification to reduce inhibitor development in the early treatment of hemophilia A: a SIPPET analysis. (2017) (41)
- The genetics of the alternative pathway of complement in the pathogenesis of HELLP syndrome (2012) (41)
- Carrier detection and prenatal diagnosis of hemophilia in developing countries. (2005) (40)
- Inactivation of ADAMTS13 by plasmin as a potential cause of thrombotic thrombocytopenic purpura (2010) (39)
- Identification of genetic risk variants for deep vein thrombosis by multiplexed next-generation sequencing of 186 hemostatic/pro-inflammatory genes (2012) (39)
- Chromosome 3 cluster rs11385942 variant links complement activation with severe COVID-19 (2021) (39)
- TTP and ADAMTS 13 : When Is Testing Appropriate ? (2007) (39)
- Mechanisms of the interaction between two ADAMTS13 gene mutations leading to severe deficiency of enzymatic activity (2006) (38)
- Clinical and molecular characterization of 6 patients affected by severe deficiency of coagulation factor V: Broadening of the mutational spectrum of factor V gene and in vitro analysis of the newly identified missense mutations. (2003) (38)
- Congenital afibrinogenaemia caused by uniparental isodisomy of chromosome 4 containing a novel 15-kb deletion involving fibrinogen Aα-chain gene (2004) (38)
- Nonneutralizing antibodies against factor VIII and risk of inhibitor development in severe hemophilia A. (2017) (38)
- Congenital afibrinogenemia: first identification of splicing mutations in the fibrinogen Bbeta-chain gene causing activation of cryptic splice sites. (2002) (38)
- Autosomal recessive deficiencies of coagulation factors. (2001) (37)
- The genetic basis of coronary artery disease: from candidate genes to whole genome analysis. (2008) (37)
- Open ADAMTS13, induced by antibodies, is a biomarker for subclinical immune-mediated thrombotic thrombocytopenic purpura. (2020) (37)
- Early-onset ischaemic stroke: Analysis of 58 polymorphisms in 17 genes involved in methionine metabolism (2010) (37)
- How the direct oral anticoagulant apixaban affects thrombin generation parameters. (2015) (37)
- Congenital afibrinogenemia: intracellular retention of fibrinogen due to a novel W437G mutation in the fibrinogen Bbeta-chain gene. (2003) (36)
- Efficacy and safety of open‐label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study (2019) (36)
- Phase 3 study of recombinant von Willebrand factor in patients with severe von Willebrand disease who are undergoing elective surgery (2018) (36)
- Relapse of thrombotic thrombocytopenic purpura after COVID-19 vaccine (2021) (36)
- Discrepancies between ADAMTS13 activity assays in patients with thrombotic microangiopathies (2013) (36)
- Relatively Poor Performance of Clinical Laboratories for DNA Analyses in the Detection of Two Thrombophilic Mutations – A Cause for Concern (2002) (35)
- Pulmonary immuno-thrombosis in COVID-19 ARDS pathogenesis (2021) (35)
- A new hemophilia carrier nomenclature to define hemophilia in women and girls: Communication from the SSC of the ISTH (2021) (35)
- A two‐centre comparative evaluation of new automated assays for von Willebrand factor ristocetin cofactor activity and antigen (2014) (35)
- Anticoagulant Treatment With Rivaroxaban in Severe Protein S Deficiency (2013) (35)
- Source of Factor VIII Replacement (PLASMATIC OR RECOMBINANT) and Incidence of Inhibitory Alloantibodies in Previously Untreated Patients with Severe Hemophilia a: The Multicenter Randomized Sippet Study (2015) (35)
- Exploring the global landscape of genetic variation in coagulation factor XI deficiency. (2017) (35)
- Molecular genetic analysis of severe coagulation factor XI deficiency in six Italian patients. (2004) (33)
- Clinical and Laboratory Features of Patients with Acquired Thrombotic Thrombocytopenic Purpura: Fourteen Years of the Milan TTP Registry (2019) (33)
- The effect of prion reduction in solvent/detergent‐treated plasma on haemostatic variables (2010) (33)
- Whole-exome sequencing to identify genetic risk variants underlying inhibitor development in severe hemophilia A patients. (2016) (33)
- Clinical and molecular characterisation of 21 patients affected by quantitative fibrinogen deficiency (2014) (32)
- Analysis of Iranian patients allowed the identification of the first truncating mutation in the fibrinogen Bbeta-chain gene causing afibrinogenemia. (2002) (32)
- The natural mutation by deletion of Lys9 in the thrombin A‐chain affects the pKa value of catalytic residues, the overall enzyme's stability and conformational transitions linked to Na+ binding (2006) (32)
- Efficacy of prophylaxis and genotype‐phenotype correlation in patients with severe Factor X deficiency in Iran (2012) (32)
- Recurrent thrombosis in patients with antiphospholipid antibodies treated with vitamin K antagonists or rivaroxaban (2018) (32)
- Pregnancy loss and risk of ischaemic stroke and myocardial infarction (2016) (32)
- Arg2074Cys missense mutation in the C2 domain of factor V causing moderately severe factor V deficiency: molecular characterization by expression of the recombinant protein. (2003) (32)
- ADAMTS13 content in plasma‐derived factor VIII/von Willebrand factor concentrates (2013) (32)
- Minimal factor XIII activity level to prevent major spontaneous bleeds (2017) (31)
- Molecular diagnosis of von Willebrand disease (2017) (30)
- A spectrum of intestinal injury models in neonatal mice (2015) (30)
- Comparison of adverse drug reactions among four COVID‐19 vaccines in Europe using the EudraVigilance database: Thrombosis at unusual sites (2021) (30)
- Central nervous system bleeding in patients with rare bleeding disorders (2012) (30)
- Changes in factor XIII level during pregnancy (2014) (30)
- Hemostatic alterations in COVID-19 (2020) (30)
- Real‐life experience in switching to new extended half‐life products at European haemophilia centres (2019) (30)
- Molecular and functional characterization of a natural homozygous Arg67His mutation in the prothrombin gene of a patient with a severe procoagulant defect contrasting with a mild hemorrhagic phenotype. (2002) (29)
- SIPPET: methodology, analysis and generalizability (2017) (29)
- Characterization of two naturally occurring mutations in the second epidermal growth factor-like domain of factor VII. (1999) (29)
- Mutations in the MCFD2 gene and a novel mutation in the LMAN1 gene in Indian families with combined deficiency of factor V and VIII (2005) (29)
- The ISTH Bleeding Assessment Tool and the risk of future bleeding (2018) (29)
- Global coagulation in myeloproliferative neoplasms (2013) (29)
- Evolution of replacement therapy for von Willebrand disease: From plasma fraction to recombinant von Willebrand factor. (2019) (28)
- First‐year results of an expanded humanitarian aid programme for haemophilia in resource‐constrained countries (2018) (28)
- Increasing dosages of low-molecular-weight heparin in hospitalized patients with Covid-19 (2021) (28)
- New findings on inhibitor development: from registries to clinical studies (2017) (28)
- Measurement and prevalence of circulating ADAMTS13‐specific immune complexes in autoimmune thrombotic thrombocytopenic purpura (2014) (28)
- Hepatic fibrinogen storage disease: identification of two novel mutations (p.Asp316Asn, fibrinogen Pisa and p.Gly366Ser, fibrinogen Beograd) impacting on the fibrinogen γ‐module (2015) (28)
- Results of an international, multicentre pharmacokinetic trial in congenital fibrinogen deficiency. (2009) (28)
- Polymorphisms in genes involved in autoimmune disease and the risk of FVIII inhibitor development in Italian patients with haemophilia A (2009) (28)
- Major differences in bleeding symptoms between factor VII deficiency and hemophilia B (2009) (27)
- Clustered F8 missense mutations cause hemophilia A by combined alteration of splicing and protein biosynthesis and activity (2017) (27)
- Elevated prepartum fibrinogen levels are not associated with a reduced risk of postpartum hemorrhage (2012) (27)
- Evaluation of assay methods to measure plasma ADAMTS13 activity in thrombotic microangiopathies (2010) (27)
- Timing and severity of inhibitor development in recombinant versus plasma‐derived factor VIII concentrates: a SIPPET analysis (2018) (27)
- How and when to measure anticoagulant effects of direct oral anticoagulants? Practical issues. (2018) (27)
- Rescue factor VIII replacement to secure hemostasis in a patient with hemophilia A and inhibitors on emicizumab prophylaxis undergoing hip replacement (2019) (27)
- Pathogenesis and treatment of acquired idiopathic thrombotic thrombocytopenic purpura (2010) (27)
- Evaluation of a New, Rapid, Fully Automated Assay for the Measurement of ADAMTS13 Activity (2019) (27)
- A rare inherited coagulation disorder: Combined homozygous factor VII and factor X deficiency (2004) (26)
- Common variants in the haemostatic gene pathway contribute to risk of early-onset myocardial infarction in the Italian population (2011) (26)
- Normal reference ranges of antithrombin, protein C and protein S: effect of sex, age and hormonal status. (2013) (26)
- Acute Portal Vein Thrombosis in SARS-CoV-2 Infection: A Case Report (2020) (26)
- Postoperative Outcomes After Laparoscopic Splenectomy Compared With Open Splenectomy (2013) (26)
- Factor V (Arg 506-->Gln) mutation in young survivors of myocardial infarction. (1996) (25)
- Laboratory testing in hemophilia: Impact of factor and non‐factor replacement therapy on coagulation assays (2020) (25)
- Orthopaedic surgery in patients with von Willebrand disease (2014) (25)
- Increased volume of distribution for recombinant activated factor VII and longer plasma-derived factor VII half-life may explain their long lasting prophylactic effect. (2013) (25)
- Glanzmann thrombasthenia and Bernard-Soulier syndrome in south Iran. (2005) (25)
- A Natural Prothrombin Mutant Reveals an Unexpected Influence of A-chain Structure on the Activity of Human α-Thrombin* (2004) (24)
- Molecular characterization of in-frame and out-of-frame alternative splicings in coagulation factor XI pre-mRNA. (2010) (24)
- Coagulation parameters in patients with cirrhosis and portal vein thrombosis treated sequentially with low molecular weight heparin and vitamin K antagonists. (2016) (24)
- Hypercoagulability in patients with Cushing disease detected by thrombin generation assay is associated with increased levels of neutrophil extracellular trap-related factors (2017) (24)
- Adherence to antibiotic treatment guidelines and outcomes in the hospitalized elderly with different types of pneumonia. (2015) (24)
- Pharmacokinetics, clot strength and safety of a new fibrinogen concentrate: randomized comparison with active control in congenital fibrinogen deficiency (2018) (24)
- Mechanistic studies on ADAMTS13 catalysis. (2008) (23)
- Comparison of Thrombin Generation Assay With Conventional Coagulation Tests in Evaluation of Bleeding Risk in Patients With Rare Bleeding Disorders (2014) (23)
- Platelet reactive conformation and multimeric pattern of von Willebrand factor in acquired thrombotic thrombocytopenic purpura during acute disease and remission (2011) (23)
- The first deletion mutation in the TSP1-6 repeat domain of ADAMTS13 in a family with inherited thrombotic thrombocytopenic purpura (2009) (23)
- COVID-19 multidisciplinary high dependency unit: the Milan model (2020) (23)
- Deep vein thrombosis in COVID-19 patients in general wards: prevalence and association with clinical and laboratory variables (2021) (23)
- Severe factor V deficiency: exon skipping in the factor V gene causing a partial deletion of the C1 domain (2003) (23)
- Comparison of attitudes towards prenatal diagnosis and termination of pregnancy for haemophilia in Iran and Italy (2004) (22)
- Efficacy, safety and pharmacokinetics of a new high‐purity factor X concentrate in subjects with hereditary factor X deficiency (2016) (22)
- Allele Frequency of CYP2C9 Gene Polymorphisms in Iran (2002) (22)
- Prediction of factor VIII inhibitor development in the SIPPET cohort by mutational analysis and factor VIII antigen measurement (2018) (22)
- Missense or splicing mutation? The case of a fibrinogen Bbeta-chain mutation causing severe hypofibrinogenemia. (2004) (22)
- World Federation of Hemophilia Gene Therapy Registry (2020) (22)
- A phase III study comparing secondary long-term prophylaxis versus on-demand treatment with vWF/FVIII concentrates in severe inherited von Willebrand disease. (2019) (22)
- Mutations in the MCFD2 gene are predominant among patients with hereditary combined FV and FVIII deficiency (F5F8D) in India (2007) (21)
- Molecular characterization of three novel splicing mutations causing factor V deficiency and analysis of the F5 gene splicing pattern (2008) (21)
- Evaluation of coagulation during treatment with directly acting antivirals in patients with hepatitis C virus related cirrhosis (2017) (21)
- Procoagulatory State in Inflammatory Bowel Diseases Is Promoted by Impaired Intestinal Barrier Function (2015) (21)
- Product type and other environmental risk factors for inhibitor development in severe hemophilia A (2018) (21)
- Advances in the Treatment of Hemophilia: Implications for Laboratory Testing. (2019) (21)
- Mutational screening of six afibrinogenemic patients: Identification and characterization of four novel molecular defects (2007) (21)
- Molecular characterization in an Italian patient with plasminogen deficiency and ligneous conjunctivitis (2005) (21)
- Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysis. (2021) (21)
- Genome editing of factor X in zebrafish reveals unexpected tolerance of severe defects in the common pathway. (2017) (21)
- Bleeding symptoms in heterozygous carriers of inherited coagulation disorders in southern Iran (2011) (20)
- Long-term neuropsychological sequelae, emotional wellbeing and quality of life in patients with acquired thrombotic thrombocytopenic purpura (2019) (20)
- Efficacy and safety of a new human fibrinogen concentrate in patients with congenital fibrinogen deficiency: an interim analysis of a Phase III trial (2018) (20)
- Hemostatic abnormalities in patients with Ehlers–Danlos syndrome (2018) (20)
- Evaluation of an automated platelet‐based assay of ristocetin cofactor activity (2011) (20)
- Nonsense-mediated mRNA decay in the ADAMTS13 gene caused by a 29-nucleotide deletion (2008) (20)
- No association between chromosome 12p13 single nucleotide polymorphisms and early‐onset ischemic stroke (2010) (20)
- Evaluation of the Utility of von Willebrand Factor Propeptide in the Differential Diagnosis of von Willebrand Disease and Acquired von Willebrand Syndrome (2018) (19)
- FRETS-VWF73 rather than CBA assay reflects ADAMTS13 proteolytic activity in acquired thrombotic thrombocytopenic purpura patients (2014) (19)
- Fibrinogen concentrate for treatment of bleeding and surgical prophylaxis in congenital fibrinogen deficiency patients (2019) (18)
- Anti-ADAMTS13 Autoantibodies against Cryptic Epitopes in Immune-Mediated Thrombotic Thrombocytopenic Purpura (2018) (18)
- Spontaneous splenic rupture in a patient with factor XIII deficiency and a novel mutation (2008) (18)
- Establishment of a bleeding score as a diagnostic tool for patients with rare bleeding disorders. (2016) (18)
- Kreuth V initiative: European consensus proposals for treatment of hemophilia using standard products, extended half-life coagulation factor concentrates and non-replacement therapies (2020) (18)
- The emerging concept of residual ADAMTS13 activity in ADAMTS13-deficient thrombotic thrombocytopenic purpura. (2013) (18)
- Dramatic presentation of acquired TTP associated with COVID-19. (2020) (18)
- Results of the Randomized, Double-Blind, Placebo-Controlled, Phase 3 Hercules Study of Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura (2017) (18)
- Arg77His and Trp187Arg are the Most Common Mutations Causing FXIII Deficiency in Iran (2012) (18)
- Core data set on safety, efficacy, and durability of hemophilia gene therapy for a global registry: Communication from the SSC of the ISTH (2020) (18)
- Prenatal diagnosis and preimplantation genetic diagnosis: novel technologies and state of the art of PGD in different regions of the world (2011) (18)
- Molecular Mapping of the Chloride-binding Site in von Willebrand Factor (VWF) (2006) (18)
- Kreuth IV: European consensus proposals for treatment of haemophilia with coagulation factor concentrates (2017) (18)
- Good practice statements (GPS) for the clinical care of patients with thrombotic thrombocytopenic purpura (2020) (18)
- The type 2B p.R1306W natural mutation of von Willebrand factor dramatically enhances the multimer sensitivity to shear stress (2013) (18)
- Active platelet‐binding conformation of plasma von Willebrand factor in young women with acute myocardial infarction (2010) (18)
- Warfarin and acenocoumarol dose requirements according to CYP2C9 genotyping in North‐Italian patients (2003) (18)
- Burden of mild haemophilia A: Systematic literature review (2019) (17)
- Reduced fibrinolytic resistance in patients with factor XI deficiency. Evidence of a thrombin‐independent impairment of the thrombin‐activatable fibrinolysis inhibitor pathway (2016) (17)
- X Chromosome inactivation: a modifier of factor VIII and IX plasma levels and bleeding phenotype in Haemophilia carriers (2020) (17)
- Combined Factor V and Factor VIII Deficiency. (2009) (17)
- Early detection of deep vein thrombosis in patients with coronavirus disease 2019: who to screen and who not to with Doppler ultrasound? (2020) (17)
- Molecular characterization of 7 patients affected by dys- or hypo-dysfibrinogenemia: Identification of a novel mutation in the fibrinogen Bbeta chain causing a gain of glycosylation. (2015) (17)
- Inhibitor development in non-severe haemophilia across Europe (2015) (17)
- Performance of clinical laboratories for DNA analyses to detect thrombophilia mutations. (2005) (17)
- Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus (2022) (17)
- Ageing successfully with haemophilia: A multidisciplinary programme (2018) (16)
- Autoimmune Protein S Deficiency and Deep Vein Thrombosis after Chickenpox (1996) (16)
- Oxidized von Willebrand factor is efficiently cleaved by serine proteases from primary granules of leukocytes: divergence from ADAMTS‐13 (2011) (16)
- The G1456 to T mutation in the thrombomodulin gene is not frequent in patients with venous thrombosis. (1997) (16)
- Homozygous 2bp Deletion in the Human Factor VII Gene: A Non-Lethal Mutation that Is Associated with a Complete Absence of Circulating Factor VII (2000) (16)
- Pregnancy complications in acquired thrombotic thrombocytopenic purpura: a case–control study (2014) (16)
- Delivery of AAV‐based gene therapy through haemophilia centres—A need for re‐evaluation of infrastructure and comprehensive care: A Joint publication of EAHAD and EHC (2021) (16)
- Fibrinogen Mumbai: intracellular retention due to a novel G434D mutation in the Bbeta-chain gene. (2006) (16)
- Targeted sequencing to identify novel genetic risk factors for deep vein thrombosis: a study of 734 genes (2018) (16)
- Role of the 2 adenine (g.11293_11294insAA) insertion polymorphism in the 3′ untranslated region of the factor VII (FVII) gene: molecular characterization of a patient with severe FVII deficiency (2005) (16)
- A synonymous (c.3390C>T) or a splice‐site (c.3380‐2A>G) mutation causes exon 26 skipping in four patients with von Willebrand disease (2A/IIE) (2013) (16)
- Frequency of Factor V Arg506 Gin in Italians (1996) (16)
- Measurement of anti‐ADAMTS13 neutralizing autoantibodies: a comparison between CBA and FRET assays (2012) (16)
- Long‐term prophylaxis in severe factor VII deficiency (2015) (15)
- How the direct oral anticoagulant apixaban affects hemostatic parameters. Results of a multicenter multiplatform study (2015) (15)
- Association of a single nucleotide polymorphism of the NPR3 gene promoter with early onset ischemic stroke in an Italian cohort. (2013) (15)
- Characterization of the neutralizing anti‐emicizumab antibody in a patient with hemophilia A and inhibitor (2020) (15)
- Management of orthopaedic surgery in rare bleeding disorders (2014) (15)
- Pain and Frailty in Hospitalized Older Adults (2020) (15)
- Pregnancy outcome after a first episode of cerebral vein thrombosis (2016) (15)
- Genetic characterization of patients with Bernard-Soulier syndrome and their relatives from Southern Iran (2007) (15)
- Bleeding symptoms in patients diagnosed as type 3 von Willebrand disease: Results from 3WINTERS‐IPS, an international and collaborative cross‐sectional study (2020) (15)
- Appropriateness of antiplatelet therapy for primary and secondary cardio‐ and cerebrovascular prevention in acutely hospitalized older people (2017) (15)
- Knowledge and therapeutic gaps: a public health problem in the rare coagulation disorders population. (2011) (15)
- Prevalence of Disease and Relationships between Laboratory Phenotype and Bleeding Severity in Platelet Primary Secretion Defects (2013) (15)
- Predictors of von Willebrand disease diagnosis in individuals with borderline von Willebrand factor plasma levels (2015) (15)
- Treatment of Hemophilia in the Near Future (2015) (15)
- Assaying FVIII activity: one method is not enough, and never was (2014) (15)
- How we make an accurate diagnosis of von Willebrand disease. (2020) (15)
- Analysis of factor V in zebrafish demonstrates minimal levels needed for early hemostasis. (2019) (15)
- Recurrence and Mortality in Young Women With Myocardial Infarction or Ischemic Stroke: Long-term Follow-up of the Risk of Arterial Thrombosis in Relation to Oral Contraceptives (RATIO) Study. (2016) (15)
- “In vitro” correction of the severe factor V deficiency‐related coagulopathy by a novel plasma‐derived factor V concentrate (2018) (15)
- Non‐invasive tool for foetal sex determination in early gestational age (2011) (14)
- Abnormal secretion and function of recombinant human factor VII as the result of modification to a calcium binding site caused by a 15-base pair insertion in the F7 gene. (2001) (14)
- Addressing the complexity of cardiovascular disease by design (2011) (14)
- Introducing the Tehran Heart Center's Premature Coronary Atherosclerosis Cohort: THC-PAC Study (2015) (14)
- Polymorphic miRNA‐mediated gene contribution to inhibitor development in haemophilia A (2012) (13)
- Molecular characterization of an Italian patient with plasminogen deficiency and ligneous conjunctivitis (2005) (13)
- The D173G mutation in ADAMTS-13 causes a severe form of congenital thrombotic thrombocytopenic purpura (2016) (13)
- Integrated postural analysis in children with haemophilia (2014) (13)
- New susceptibility loci for severe COVID-19 by detailed GWAS analysis in European populations (2021) (13)
- Summary report of the First International Conference on inhibitors in haemophilia A. (2017) (13)
- Erratum: Evaluation and management of postpartum hemorrhage: Consensus from an international expert panel (Transfusion (2014) 54 (1756-1768)) (2015) (13)
- Congenital hypofibrinogenemia: characterization of two missense mutations affecting fibrinogen assembly and secretion. (2008) (13)
- Where do we stand with antithrombotic prophylaxis in patients with COVID-19? (2020) (13)
- Pattern of comorbidities and 1-year mortality in elderly patients with COPD hospitalized in internal medicine wards: data from the RePoSI Registry (2020) (13)
- Detailed stratified GWAS analysis for severe COVID-19 in four European populations (2022) (13)
- ADAMTS13-specific circulating immune complexes as potential predictors of relapse in patients with acquired thrombotic thrombocytopenic purpura. (2017) (12)
- Thrombin generation and other coagulation parameters in a patient with homozygous congenital protein S deficiency on treatment with rivaroxaban (2016) (12)
- Clinical phenotype, fibrinogen supplementation and health-related quality of life in patients with afibrinogenemia. (2021) (12)
- Congenital factor XIII deficiency in Pakistan: characterization of seven families and identification of four novel mutations (2014) (12)
- Post-partum hemorrhage in women with rare bleeding disorders. (2011) (12)
- Risk of pregnancy-related venous thromboembolism and obstetrical complications in women with inherited type I antithrombin deficiency: a retrospective, single-centre, cohort study. (2020) (12)
- Management of bleeding disorders in adults (2012) (12)
- Application of a hemophilia mortality framework to the Emicizumab Global Safety Database (2020) (12)
- Inhibitors of factor VIII in hemophilia. (2009) (12)
- ADAMTS13 Secretion and Residual Activity among Patients with Congenital Thrombotic Thrombocytopenic Purpura with and without Renal Impairment. (2015) (12)
- Clinical and laboratory patterns of the haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura in southern Iran (2006) (11)
- Molecular characterization of the first missense mutation in the fibrinogen Aalpha-chain gene identified in a compound heterozygous afibrinogenemic patient. (2007) (11)
- Pharmacodynamics of recombinant activated factor VII and plasma-derived factor VII in a cohort of severe FVII deficient patients. (2013) (11)
- High rate of sustained virological response with direct‐acting antivirals in haemophiliacs with HCV infection: A multicenter study (2019) (11)
- Hemophilia gene therapy knowledge and perceptions: Results of an international survey (2020) (11)
- Global Seroprevalence of Pre-existing Immunity Against AAV5 and Other AAV Serotypes in People with Hemophilia A (2022) (10)
- An international collaborative study to compare different von Willebrand factor glycoprotein Ib binding activity assays: the COMPASS‐VWF study (2018) (10)
- Raised haematocrit concentration and the risk of death and vascular complications after major surgery (2013) (10)
- Complications of whole-exome sequencing for causal gene discovery in primary platelet secretion defects (2019) (10)
- Evolution of Haemophilia Care in Europe: 10 years of the principles of care (2020) (10)
- How I treat thrombotic thrombocytopenic purpura in pregnancy. (2020) (10)
- Pediatric requirements in Europe stymie help for hemophilia (2014) (10)
- Molecular characterization, recombinant protein expression, and mRNA analysis of type 3 von Willebrand disease: Studies of an Italian cohort of 10 patients (2012) (10)
- A critical role for Gly25 in the B chain of human thrombin (2005) (10)
- Inhibitor development in haemophilia (2017) (10)
- Dosing anticoagulant therapy with coumarin drugs: is genotyping clinically useful? No (2008) (10)
- Single Nucleotide Variant rs2232710 in the Protein Z-Dependent Protease Inhibitor (ZPI, SERPINA10) Gene Is Not Associated with Deep Vein Thrombosis (2016) (10)
- Minimal dataset for post‐registration surveillance of new drugs in hemophilia: communication from the SSC of the ISTH (2017) (10)
- Caplacizumab, Anti-Vwf Nanobody Potentially Changing the Treatment Paradigm in Thrombotic Thrombocytopenic Purpura: Results of the TITAN Trial (2014) (10)
- Key insights to understand the immunogenicity of FVIII products (2016) (10)
- Emicizumab, the factor VIII mimetic bi-specific monoclonal antibody and its measurement in plasma (2020) (10)
- A recurrent F8 mutation (c.6046C>T) causing hemophilia A in 8% of northern Italian patients: evidence for a founder effect (2015) (10)
- ADAMTS13 activity, high VWF and FVIII levels in the pathogenesis of deep vein thrombosis. (2020) (10)
- Management of rare acquired bleeding disorders. (2019) (10)
- Requirements for research investigations to clarify the relationships and management of menstrual abnormalities in women with hemostatic disorders. (2005) (9)
- Immunochip analysis identifies novel susceptibility loci in the human leukocyte antigen region for acquired thrombotic thrombocytopenic purpura (2016) (9)
- Thrombophilia screening: little role for the JAK2V617F mutation. (2008) (9)
- Management of pregnancy in type 2B von Willebrand disease: case report and literature review (2015) (9)
- Duration of oral contraceptive use and the risk of venous thromboembolism. A case-control study. (2016) (9)
- Von Willebrand disease type 2N: An update (2021) (9)
- Pitfalls in molecular diagnosis in a family with severe factor VII (FVII) deficiency—misdiagnosis by direct sequence analysis using a PCR product (2003) (9)
- Body mass index reduction improves the baseline procoagulant imbalance of obese subjects (2019) (9)
- Assessment of Platelet Thrombus Formation under Flow Conditions in Adult Patients with COVID-19: An Observational Study (2021) (9)
- The features of acquired thrombotic thrombocytopenic purpura occurring at advanced age. (2020) (9)
- Low thrombin generation during major orthopaedic surgery fails to predict the bleeding risk in inhibitor patients treated with bypassing agents (2016) (9)
- A novel mutation of α2‐plasmin inhibitor gene causes an inherited deficiency and a bleeding tendency (2007) (9)
- Genetic background and risk of postpartum haemorrhage: results from an Italian cohort of 3219 women (2014) (9)
- COVID-19 Network: the response of an Italian Reference Institute to research challenges about a new pandemia (2020) (9)
- Potential misdiagnosis of dysfibrinogenaemia: Data from multicentre studies amongst UK NEQAS and PRO‐RBDD project laboratories (2017) (9)
- An international registry of patients with plasminogen deficiency (HISTORY) (2020) (8)
- Subclinical myopathic changes in COVID-19 (2021) (8)
- Mediterranean spotted fever and hearing impairment: a rare complication. (2015) (8)
- A recurrent Gly43Asp substitution in coagulation Factor X rigidifies its catalytic pocket and impairs catalytic activity and intracellular trafficking. (2014) (8)
- Autoimmune hemophilia at rescue (2009) (8)
- Evaluation of an heterogeneous group of patients with von Willebrand disease using an assay alternative to ristocetin induced platelet agglutination (2015) (8)
- Procoagulant imbalance influences cardiovascular and liver damage in chronic hepatitis C independently of steatosis (2019) (8)
- Factor XI deficiency in Southern Iran: identification of a novel missense mutation (2009) (8)
- Procoagulant imbalance in preterm neonates detected by thrombin generation procedures. (2019) (8)
- Immune Responses to Plasma-Derived Versus Recombinant FVIII Products (2021) (8)
- The thrombin generation assay distinguishes inhibitor from non‐inhibitor patients with severe haemophilia A (2016) (8)
- B and T lymphocytes in acquired thrombotic thrombocytopenic purpura during disease remission. (2011) (8)
- Rare bleeding disorders. (2009) (8)
- High-titre inhibitors in previously untreated patients with severe haemophilia A receiving recombinant or plasma-derived factor VIII: a budget-impact analysis. (2018) (8)
- HOW I TREAT GASTRO-INTESTINAL BLEEDING IN CONGENITAL AND ACQUIRED VON WILLEBRAND DISEASE. (2020) (8)
- Increased Risk of Urticaria/Angioedema after BNT162b2 mRNA COVID-19 Vaccine in Health Care Workers Taking ACE Inhibitors (2021) (8)
- Vaccination against COVID‐19: Rationale, modalities and precautions for patients with haemophilia and other inherited bleeding disorders (2021) (8)
- Post-authorization pharmacovigilance for hemophilia in Europe and the USA: Independence and transparency are keys. (2021) (7)
- Thrombin generation in patients with idiopathic sudden sensorineural hearing loss. (2014) (7)
- Massive cerebral venous thrombosis due to vaccine-induced immune thrombotic thrombocytopenia (2021) (7)
- Risk factors for mortality in hospitalized patients with COVID-19: a study in Milan, Italy (2020) (7)
- Factor VII gene polymorphisms are not associated with myocardial infarction in young women (2005) (7)
- In vitro characterizations of the first therapeutic factor V concentrate (2014) (7)
- Establishment of a framework for assessing mortality in persons with congenital hemophilia A and its application to an adverse event reporting database (2020) (7)
- Apparently dominant transmission of a recessive disease: deficiency of factor VII in Iranian Jews. (2000) (7)
- Next-Generation Sequencing and In Vitro Expression Study of ADAMTS13 Single Nucleotide Variants in Deep Vein Thrombosis (2016) (7)
- The P303T mutation in the human factor VII (FVII) gene alters the conformational state of the enzyme and causes a severe functional deficiency (2004) (7)
- Design of clinical trials for new products in hemophilia: communication from the SSC of the ISTH (2015) (7)
- Detection of Factor XIII deficiency: data from multicentre exercises amongst UK NEQAS and PRO‐RBDD project laboratories (2017) (7)
- Prognostic value of copeptin and mid‐regional proadrenomedullin in COVID‐19‐hospitalized patients (2022) (7)
- Frequency of the p.Gly262Asp mutation in congenital Factor X deficiency (2015) (7)
- Factors Associated with Depressive Symptoms in Young Adults with Coronary Artery Disease: Tehran Heart Center's Premature Coronary Atherosclerosis Cohort (THC-PAC) Study (2016) (7)
- Two novel heterozygote missense mutations of the ADAMTS13 gene in a child with recurrent thrombotic thrombocytopenic purpura. (2013) (7)
- Adoption of emicizumab (Hemlibra®) for hemophilia A in Europe: Data from the 2020 European Association for Haemophilia and Allied Disorders survey (2021) (7)
- Preoperative Hematocrit Concentration and the Risk of Stroke in Patients Undergoing Isolated Coronary-Artery Bypass Grafting (2013) (7)
- Involvement of the IgE‐basophil system and mild complement activation in haemophilia B with anti‐factor IX neutralizing antibodies and anaphylaxis (2017) (7)
- Joint WFH‐ISTH session: issues in clinical trial design (2014) (7)
- Profiling the mutational landscape of coagulation factor V deficiency (2020) (7)
- Fibrinogen concentrates. (2009) (7)
- Perceived well-being and mental health in haemophilia (2020) (7)
- Is placental blood a reliable source for the evaluation of neonatal hemostasis at birth? (2020) (6)
- Mortality in Patients with COVID-19 on Renin Angiotensin System Inhibitor Long-Term Treatment: An Observational Study Showing that Things Are Not Always as They Seem (2021) (6)
- Integrated Efficacy Results from the Phase II and Phase III Studies with Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura (2018) (6)
- Clinical manifestations and complications of childbirth and replacement therapy in 385 Iranian patients with type 3 von Willebrand disease (2000) (6)
- Genomic approaches to bleeding disorders (2016) (6)
- Recommendations for authors of manuscripts reporting inhibitor cases developed in previously treated patients with hemophilia: communication from the SSC of the ISTH (2016) (6)
- Drop of residual plasmatic activity of ADAMTS13 to undetectable levels during acute disease in a patient with adult-onset congenital thrombotic thrombocytopenic purpura. (2013) (6)
- Acute Portal Vein Thrombosis in SARS-CoV-2 Infection: A Case Report. (2020) (6)
- Real-World Rates of Bleeding, Factor VIII Use, and Quality of Life in Individuals with Severe Haemophilia A Receiving Prophylaxis in a Prospective, Noninterventional Study (2021) (6)
- Procoagulant Imbalance in Klinefelter Syndrome Assessed by Thrombin Generation Assay and Whole-Blood Thromboelastometry (2020) (6)
- Prevalence of the age-related diseases in older patients with acquired thrombotic thrombocytopenic purpura. (2020) (6)
- Rare variants lowering the levels of coagulation factor X are protective against ischemic heart disease (2019) (6)
- Gene therapy of hemophilia: Hub centres should be haemophilia centres: A joint publication of EAHAD and EHC (2022) (6)
- Atypical primary cutaneous cryptococcosis during ibrutinib therapy for chronic lymphocytic leukemia (2019) (6)
- Generation of anti-idiotypic antibodies to detect anti-spacer antibody idiotopes in acute thrombotic thrombocytopenic purpura patients (2018) (6)
- Health‐related quality of life and health status in adolescent and adult people with haemophilia A without factor VIII inhibitors—A non‐interventional study (2021) (6)
- Rate and appropriateness of polypharmacy in older patients with hemophilia compared with age‐matched controls (2018) (6)
- Acquired Von Willebrand syndrome and response to desmopressin (2018) (6)
- Efficacy and safety of fibrinogen concentrate for on‐demand treatment of bleeding and surgical prophylaxis in paediatric patients with congenital fibrinogen deficiency (2020) (6)
- Hypercoagulability in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD): Causes and Consequences (2022) (6)
- Homozygosity for a Thr575Met missense mutation in the catalytic domain associated with factor XI deficiency. (2005) (6)
- Impact of a commercially available DOAC absorbent on two integrated procedures for lupus anticoagulant detection. (2021) (6)
- Molecular Aggregation of Marketed Recombinant FVIII Products: Biochemical Evidence and Functional Effects (2019) (5)
- Role of factor VIII-binding capacity of endogenous von Willebrand factor in the development of factor VIII inhibitors in patients with severe hemophilia A (2019) (5)
- Erratum: Glazmann thrombasthenia and Bernard Soulier syndrome in South Iran (Clinical and Laboratory Haematology (2005) 27, (324-327)) (2006) (5)
- Advances in Clinical and Basic Science of Coagulation: Illustrated abstracts of the 9th Chapel Hill Symposium on Hemostasis (2018) (5)
- Molecular investigation of 41 patients affected by coagulation factor XI deficiency (2018) (5)
- von Willebrand factor propeptide to antigen ratio in acquired thrombotic thrombocytopenic purpura (2012) (5)
- Anti-TNF-α Treatment Reduces the Baseline Procoagulant Imbalance of Patients With Inflammatory Bowel Diseases. (2021) (5)
- Degradation of two novel congenital TTP ADAMTS13 mutants by the cell proteasome prevents ADAMTS13 secretion. (2016) (5)
- Evaluation of an automated chromogenic assay for Factor VIII clotting activity measurement in patients affected by haemophilia A (2019) (5)
- Severe acquired von Willebrand syndrome secondary to systemic lupus erythematosus (2018) (5)
- A comparative evaluation of a new fully automated assay for von Willebrand factor collagen binding activity to an established method (2018) (5)
- Hospital Care of Older Patients With COPD: Adherence to International Guidelines for Use of Inhaled Bronchodilators and Corticosteroids. (2019) (5)
- Evaluation of a fully automated von Willebrand factor assay panel for the diagnosis of von Willebrand disease (2020) (5)
- Genotyp-Phenotype Correlation in Congenital ADAMTS13 Deficient Patients (2008) (5)
- No changes of parameters nor coagulation activation in healthy subjects vaccinated for SARS-Cov-2 (2021) (5)
- IgM Autoantibodies to Complement Factor H in Atypical Hemolytic Uremic Syndrome (2021) (5)
- Assessment of Clotting Factor Concentrates—Pivotal Studies and Long-Term Requirements (2015) (5)
- Factors Associated with Anxiety in Premature Coronary Artery Disease Patients: THC-PAC Study. (2016) (5)
- European principles of inhibitor management in patients with haemophilia: implications of new treatment options (2020) (5)
- Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studies (2022) (5)
- Incidence of low‐titre factor VIII inhibitors in patients with haemophilia A: meta‐analysis of observational studies (2017) (5)
- The HLA Variant rs6903608 Is Associated with Disease Onset and Relapse of Immune-Mediated Thrombotic Thrombocytopenic Purpura in Caucasians (2020) (5)
- von Willebrand disease type 1 mutation p.Arg1379Cys and the variant p.Ala1377Val synergistically determine a 2M phenotype in four Italian patients (2016) (5)
- Changing epidemiology of the hemolytic uremic syndrome and thrombotic thrombocytopenic purpura in southern Iran (2006) (5)
- Molecular characterization of a factor VII deficient patient supports the importance of the second epidermal growth factor-like domain. (2004) (5)
- Design of a prospective observational study on the effectiveness and real-world usage of recombinant factor VIII Fc (rFVIIIFc) compared with conventional products in haemophilia A: the A-SURE study (2019) (5)
- Abstract 4011: Influence Of Rs1333040, A Newly Discovered 9p21.3 Genetic Variant, On Clinical Outcomes In Early-onset Myocardial Infarction (2008) (5)
- Clinical factors associated with death in 3044 COVID-19 patients managed in internal medicine wards in Italy: comment (2021) (5)
- Hyperglycemia at admission, comorbidities, and in-hospital mortality in elderly patients hospitalized in internal medicine wards: data from the RePoSI Registry (2021) (4)
- The role of ADAMTS13 in the new pathogenesis of TTP (2005) (4)
- Polypharmacy in older adults with severe haemophilia (2018) (4)
- Dramatic presentation of acquired thrombotic thrombocytopenic purpura associated with COVID-19 (2020) (4)
- A Randomized, Double-Blind, Placebo-Controlled, Clinical Outcome Study of ARC1779 In Patients with Thrombotic Thrombocytopenic Purpura (TTP) (2010) (4)
- Is Hemophilia B Less Severe Than Hemophilia A? Results Of Global Coagulation Assays (2013) (4)
- Reply to: The importance and challenge of pediatric trials of hemophilia drugs (2014) (4)
- Vagaries of genetic association studies in myocardial infarction. (2003) (4)
- Thromboelastometry. Reproducibility of duplicate measurement performed by the RoTem® device. (2018) (4)
- Functional characterization of a novel missense mutation identified in a Turkish patient affected by severe coagulation factor V deficiency (2012) (4)
- Persistent and severe hypoglycemia associated with trimethoprim-sulfamethoxazole in a frail diabetic man on polypharmacy: A case report and literature review . (2017) (4)
- Safety of Caplacizumab for the Treatment of Patients with Acquired Thrombotic Thrombocytopenic Purpura - Results Normalized to Time of Exposure in a Double-Blind, Placebo-Controlled, Phase 3 Hercules Study (2018) (4)
- Thrombin generation assay for testing hemostatic effect of factor VIII concentrates in patients with hemophilia A and inhibitors: In vitro results from the PredicTGA study. (2019) (4)
- Plasma levels of extracellular vesicles and the risk of post-operative pulmonary embolism in patients with primary brain tumors: a prospective study (2021) (4)
- Efficacy and safety of azathioprine during remission of immune-mediated thrombotic thrombocytopenic purpura (2021) (4)
- International Society on Thrombosis and Haemostasis core curriculum project: Core competencies in laboratory thrombosis and hemostasis (2019) (4)
- Genome-Wide Association Studies in Myocardial Infarction and Coronary Artery Disease (2010) (4)
- Effect of different methods for outlier detection and rejection when calculating cut off values for diagnosis of lupus anticoagulants. (2020) (4)
- Risk Factors and Manageability of the Mainly Mild Mucocutaneous Bleeding Profile Observed in Attp Patients Treated with Caplacizumab during the Phase III Hercules Study (2018) (4)
- Idelalisib rapidly improves platelet function tests in patients with chronic lymphocytic leukaemia (2018) (4)
- Comparison between the first and second COVID-19 waves in Internal Medicine wards in Milan, Italy: a retrospective observational study (2022) (4)
- Risk of diagnostic delay in congenital thrombotic thrombocytopenic purpura (2019) (4)
- Hypercoagulability and the risk of recurrence in young women with myocardial infarction or ischaemic stroke: a cohort study (2019) (4)
- Thrombotic microangiopathy without renal involvement: two novel mutations in complement‐regulator genes (2016) (4)
- A two-step approach (Enzyme-linked immunosorbent assay and confirmation assay) to detect antibodies against von Willebrand factor in patients with Acquired von Willebrand Syndrome. (2014) (4)
- Congenital and acquired ADAMTS13 deficiency: Two mechanisms, one patient (2015) (4)
- In Vitro Expression Studies of Two Mutations on the Metalloprotease and First Cub Domains of the ADAMTS-13 Gene Leading to Severe ADAMTS-13 Deficiency and Chronic Recurrent TTP. (2004) (3)
- Intracranial Haemorrhage in Haemophilia Patients Is Still an Open Issue: The Final Results of the Italian EMO.REC Registry (2022) (3)
- IDEAL study: A real‐world assessment of pattern of use and clinical outcomes with recombinant coagulation factor IX albumin fusion protein (rIX‐FP) in patients with haemophilia B in Italy (2022) (3)
- Novel variant in HPS3 gene in a patient with Hermansky Pudlak syndrome (HPS) type 3 (2019) (3)
- Case report: use of thienopyridines in a patient with acquired idiopathic thrombotic thrombocytopenic purpura (2012) (3)
- Prevalence of use and appropriateness of antidepressants prescription in acutely hospitalized elderly patients. (2019) (3)
- Simvastatin Prevents Liver Microthrombosis and Sepsis Induced Coagulopathy in a Rat Model of Endotoxemia (2022) (3)
- Role of ADAMTS13, VWF and F8 genes in deep vein thrombosis (2021) (3)
- Current and Emerging Approaches for Pain Management in Hemophilic Arthropathy (2022) (3)
- Baseline factor VIII plasma levels and age at first bleeding in patients with severe forms of von Willebrand disease (2016) (3)
- Thrombotic thrombocytopenic purpura and defective apoptosis due to CASP8/10 mutations: the role of mycophenolate mofetil. (2019) (3)
- Genetic aspects and research development in haemostasis (2008) (3)
- Pharmacokinetics, surrogate efficacy and safety evaluations of a new human plasma-derived fibrinogen concentrate (FIB Grifols) in adult patients with congenital afibrinogenemia. (2021) (3)
- Analysis of the structural effects of four novel and a previously known mutations causing factor XI deficiency (2009) (3)
- Next-generation DNA sequencing to identify novel genetic risk factors for cerebral vein thrombosis. (2018) (3)
- The EHA Research Roadmap: Blood Coagulation and Hemostatic Disorders (2021) (3)
- Pharmacokinetic (PK) Comparison of Two Fibrinogen Concentrates in Patients with Congenital Fibrinogen Deficiency: Final Analysis (2015) (3)
- Rare coagulation disorders: an emerging issue. (2007) (3)
- The European Association for Haemophilia and Allied Disorders Coagulation Factor Variant Databases (2015) (3)
- Factor V and Combined Factor V and VIII Deficiencies (2010) (3)
- Effects of Antibody Responses to Pre-Existing Coronaviruses on Disease Severity and Complement Activation in COVID-19 Patients (2022) (3)
- A novel CD46 mutation in a patient with microangiopathy clinically resembling thrombotic thrombocytopenic purpura and normal ADAMTS13 activity (2015) (3)
- Rare Inherited Coagulation Disorders (2015) (3)
- Diagnosis, therapeutic advances, and key recommendations for the management of factor X deficiency. (2021) (3)
- Pharmacokinetic (PK) Comparison of Two Fibrinogen Concentrates for the Treatment of Congenital Fibrinogen Deficiency (2014) (3)
- Acquired thrombotic thrombocytopenic purpura in a child: rituximab to prevent relapse. A pediatric report and literature review (2018) (3)
- Genotypes of European and Iranian patients with type 3 von Willebrand disease enrolled in 3WINTERS-IPS. (2021) (3)
- Risk Factors for Recurrence of Thrombotic Thrombocytopenic Purpura. (2006) (3)
- Reply to the letter by Iorio (2017) (3)
- Increasing levels of von Willebrand factor and factor VIII with age in patients affected by von Willebrand disease (2020) (3)
- Updates on Novel Non-Replacement Drugs for Hemophilia (2022) (3)
- Understanding the Impact of Aberrant Splicing in Coagulation Factor V Deficiency (2019) (3)
- The correlation between gene mutations and inhibitor development in patients with haemophilia A in southern Iran (2011) (3)
- Hemostasis in pregnant women with COVID‐19 (2020) (3)
- Minimal factor XIII activity level to prevent major spontaneous bleeds: reply (2017) (3)
- Two Naturally Occurring Mutations on FVII Gene (S363I-W364C) Altering Intrinsic Catalytic Activity (2002) (3)
- Pregnancy outcome after a first episode of cerebral vein thrombosis: reply (2017) (2)
- Distinct Metabolic Profile Associated with a Fatal Outcome in COVID-19 Patients during the Early Epidemic in Italy (2021) (2)
- Does the orphan medicinal product regulation assist or hinder access to innovative haemophilia treatment in Europe ? (2014) (2)
- Thrombin Generation in Preterm Newborns With Intestinal Failure-Associated Liver Disease (2020) (2)
- Response: Further thoughts on the “phantom” Δ6/7 FXI isoform (2010) (2)
- Safety and efficacy of long‐term emicizumab prophylaxis in hemophilia A with factor VIII inhibitors: A phase 3b, multicenter, single‐arm study (STASEY) (2022) (2)
- Phase 3 study of recombinant von Willebrand factor in patients with severe von Willebrand disease who are undergoing elective surgery: Reply (2019) (2)
- Underdiagnosis and undertreatment of osteoporotic patients admitted in internal medicine wards in Italy between 2010 and 2016 (the REPOSI Register) (2021) (2)
- Consumption of complement in a 26-year-old woman with severe thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. (2021) (2)
- Clinical risk scores for the early prediction of severe outocomes in patients hospitalized for COVID-19: comment (2021) (2)
- Interplay between coagulation and determinants of liver disease in patients with metabolic dysfunction (2022) (2)
- Treatment of chronic hepatitis C with pegylated interferon‐α in a patient with recurrent autoimmune thrombotic thrombocytopenic purpura (2013) (2)
- Research in haemophilia B – approaching the request for high evidence levels in a rare disease (2015) (2)
- A comparative evaluation of two new automated assays for von Willebrand factor ristocetin cofactor activity and von Willebrand factor antigen (2013) (2)
- The EAHAD coagulation factor variant databases (2014) (2)
- A distinct metabolic profile associated with a fatal outcome in COVID-19 patients during early epidemic in Italy (2021) (2)
- Minimal residual FXIII coagulant activity to prevent spontaneous major bleeding, on behalf of the PRO-RBDD group (2016) (2)
- Use of high flow nasal cannula in patients with acute respiratory failure in general wards under intensivists supervision: a single center observational study (2022) (2)
- Factor VIII inhibitor and source of replacement therapy. (2012) (2)
- DETERMINATION OF ANTI-ADAMTS13 AUTOANTIBODIES IN THROMBOTIC TROMBOCITOPENIC PURPURA (TTP) PATIENTS: COMPARISON OF TWO DIFFERENT METHODS (2007) (2)
- Relationship between thrombin generation parameters and prothrombin fragment 1 + 2 plasma levels (2021) (2)
- Usefulness of fibrosis-4 (FIB-4) score and metabolic alterations in the prediction of SARS-CoV-2 severity (2022) (2)
- Prospective Data Collection on Patients with Fibrinogen and Factor XIII Deficiencies: Prelimary Results of the PRO-RBDD Project (2014) (2)
- Untreated bleeds in people with hemophilia A in a noninterventional study and intrapatient comparison after initiating emicizumab in HAVEN 1–3 (2022) (2)
- Real-Life Population Pharmacokinetics of Recombinant Factor XIII and Dosing Considerations for Preventing the Risk of Bleeding in Patients with FXIII Congenital Deficiency (2021) (2)
- Salvage therapy with high dose Intravenous Immunoglobulins in acquired Von Willebrand Syndrome and unresponsive severe intestinal bleeding (2014) (2)
- Heart failure and chronic kidney disease in a registry of internal medicine wards (2014) (2)
- Thrombotic Thrombocytopenic Purpura and Haemolytic–Uraemic Syndrome (Congenital and Acquired) (2007) (2)
- Clinical risk scores for the early prediction of severe outocomes in patients hospitalized for COVID-19: comment (2021) (2)
- Safety Results Normalized to Time of Exposure during the Phase 3 HERCULES Study of Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura (2019) (2)
- Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A. (2023) (2)
- Plasma factor XIII level variations during menstrual cycle (2016) (2)
- Rehabilitation through Accessible Mobile Gaming and Wearable Sensors (2021) (2)
- Abstract 4882: Factor V Leiden, But Not Prothrombin G20120A, Is Associated With Premature Myocardial Infarction (2008) (1)
- Evaluation of the effect on endogenous factor VIII activity (FVIII: C) after recombinant von Willebrand factor (rVWF) administration during the elective surgery study in patients with severe von Willebrand disease (VWD) (2018) (1)
- Efficacy and safety of valoctocogene roxaparvovec gene transfer for severe hemophilia A: results from the GENEr8-1 three-year analysis (2023) (1)
- Elevated Hematocrit Concentration and the Risk of Mortality and Vascular Events in Patients Undergoing Major Surgery (2012) (1)
- Mutational Repertoire in the SIPPET Cohort and Prediction of FVIII Inhibitor Risk (2017) (1)
- Patients with Mild Hemophilia a with Discrepant FVIII Assays: Thrombin Generation and Bleeding Phenotype (2014) (1)
- Remdesivir-induced bradycardia in patients hospitalized with SARS-CoV2 infection: a possible vagally-mediated mechanism (2022) (1)
- Identification of genetic risk variants for deep vein thrombosis by multiplexed next-generation sequencing of 186 hemostatic/pro-inflammatory genes (2012) (1)
- MOLECULAR STUDY OF VASCULAR ENDOTHELIAL GROWTH FACTOR GENE IN IRANIAN PATIENTS AFTER MYOCARDIAL INFARCTION (2006) (1)
- A Computer-Aided Diagnosis Tool for the Detection of Hemarthrosis By Remote Joint Ultrasound in Patients with Hemophilia (2022) (1)
- Narratives of Patients with Fatal Outcomes During the Phase 2 TITAN and Phase 3 HERCULES Studies (2019) (1)
- Prescription appropriateness of anticoagulant drugs for prophylaxis of venous thromboembolism in hospitalized multimorbid older patients (2022) (1)
- Long‐term follow‐up of patients treated with caplacizumab and safety and efficacy of repeat caplacizumab use: Post‐HERCULES study (2022) (1)
- Phenotypic and genetic characterizations of the Milan cohort of von Willebrand disease type 2 (2022) (1)
- IgG subclasses as biomarkers for persistence of factor VIII inhibitors in previously untreated patients with severe haemophilia A (2020) (1)
- A MULTICENTRE PROSPECTIVE OPEN-LABEL STUDY ASSESSING PHARMACOKINETICS, CLINICAL EFFICACY AND SAFETY OF A TRIPLE-SECURED FIBRINOGEN CONCENTRATE: FIBRINOGENE T-I (2007) (1)
- Genetic Risk Stratification to Minimize Inhibitor Risk with the Use of Recombinant Factor VIII Concentrates: A Sippet Analysis (2016) (1)
- Evaluation of procoagulant imbalance in Cushing’s syndrome after short- and long-term remission of disease (2021) (1)
- Worldwide SARS-CoV-2 haplotype distribution in early pandemic (2022) (1)
- Differential diagnosis between type 2A and 2B von Willebrand disease in a child with a previously undescribed de novo mutation (2018) (1)
- Management of haemophilia A with inhibitors: A regional cross‐talk (2022) (1)
- Recreational opium use as a risk factor for coronary artery disease: results from the premature coronary artery disease Milano-Iran (MIran) study (2020) (1)
- Residual Plasmatic Activity of ADAMTS13 in Congenital Thrombotic Thrombocytopenic Purpura Correlates with Disease Phenotype (2011) (1)
- Recombinant von Willebrand factor prophylaxis in patients with severe von Willebrand disease: phase 3 study results (2022) (1)
- Plasma Exchange in a Patient with Immune Thrombocytopenia Associated with Antiphospholipid Syndrome Hospitalized for COVID-19 (2022) (1)
- External validation of risk scores to predict in-hospital mortality in patients hospitalized due to coronavirus disease 2019 (2022) (1)
- Effect of emicizumab on global coagulation assays for plasma supplemented with apixaban or argatroban (2019) (1)
- Smoking and the Risk ofMortality and Vascular and Respiratory Events in Patients UndergoingMajor Surgery (2013) (1)
- ADAMTS13 Content of Plasma-Derived Factor VIII-Von Willebrand Factor Concentrates (2012) (1)
- Prevention of relapse in patients with acquired thrombotic thrombocytopenic purpura undergoing elective surgery: a case series (2019) (1)
- Discrepancies between different types of ADAMTS13 assays in patients with thrombotic microangiopathies (2011) (1)
- Clots from FXI-Deficient Patients Display a Reduced Fibrinolytic Resistance (2014) (1)
- Prothrombin mutation conveying antithrombin resistance. (2012) (1)
- Reduced FVIII recovery associated with anti-FVIII PEG antibodies after BNT162b2 SARS-CoV-2 vaccination (2022) (1)
- Immunogenicity, Efficacy and Safety of Rurioctocog Alfa Pegol in Previously Untreated Patients with Severe Hemophilia a: Interim Results from an Open-Label Multicenter Clinical Trial (2021) (1)
- Hemorrhagic and thrombotic adverse events associated with emicizumab and extended half-life factor VIII replacement drugs: EudraVigilance data of 2021. (2023) (1)
- The Arrival of Gene Therapy for Patients with Hemophilia A (2022) (1)
- Alternative splicing and nonsense-mediated decay in the F5 gene (2007) (1)
- In vitro characterization of the first plasma-derived factor V concentrate in development (2014) (1)
- Pediatric stroke and ADAMTS genes. (2012) (1)
- PROTHROMBIN MUTANT REVEALS AN UNEXPECTED INFLUENCE OF THE A-CHAIN ’ S STRUCTURE ON THE ACTIVITY OF HUMAN α-THROMBIN (2004) (1)
- An unusual diagnosis in a 31-year-old man with abdominal pain and hyponatremia (2018) (1)
- Efficacy of Caplacizumab in Patients with aTTP in the HERCULES Study According to Initial Immunosuppression Regimen (2019) (1)
- Pro-coagulant imbalance in patients with community acquired pneumonia assessed on admission and one month after hospital discharge (2021) (1)
- Risk Differential in Inhibitor Development in the First Days of Treatment By Product Class: A Sippet Analysis (2016) (1)
- Functional analysis of missense mutations in the Myocyte Enhancer Factor 2A (MEF2A) gene do not support their causal role in the pathogenesis of myocardial infarction (2008) (1)
- Adult-Onset Still Disease After Human Herpesvirus 6 Infection in an Elderly Patient: A Case Report. (2019) (1)
- The evolution of physiotherapy in the multidisciplinary management of persons with haemophilia (PWH): A scoping review (2022) (1)
- Factor XIII deficiency : preliminary results of the PRO-RBDD project (2015) (1)
- Acquired hemophilia A and delta storage pool deficiency in a patient with indolent non-Hodgkin lymphoma (2021) (1)
- Lombardy diagnostic and therapeutic network of thrombotic microangiopathy (2022) (1)
- Handwriting Analysis in Children and Adolescents with Hemophilia: A Pilot Study (2020) (1)
- Analysis of factor V in zebrafish demonstrates minimal levels needed for hemostasis and risk stratifies human variants (2019) (1)
- Patterns of infections in older patients acutely admitted to medical wards: data from the REPOSI register (2019) (1)
- DATABASE ON RARE BLEEDING DISORDER (RBDS): PHENOTYPE AND GENOTYPE ANALYSIS ON 400 AFFECTED PATIENTS (2007) (1)
- Von Willebrand factor propeptide and pathophysiological mechanisms in European and Iranian patients with type 3 von Willebrand disease enrolled in the 3WINTERS‐IPS study (2022) (1)
- Patterns of infections in older patients acutely admitted to medical wards: data from the REPOSI register (2019) (1)
- Liver-Related Aspects of Gene Therapy for Haemophilia: Call to Action for Collaboration between Haematologists and Hepatologists. (2022) (1)
- Risk of myocardial infarction and polymorphisms in candidate genes. (2003) (1)
- Eahad-DB: a combined coagulation factor variant databases resource for the clinical and scientificcommunities (2015) (1)
- PRO95 FROM DRUG ACCESS TO VALUE BASED HEALTHCARE: INTEGRATED CARE PATHWAYS FOR HEMOPHILIA IN ITALY (2019) (0)
- congenital fibrinogen deficiency in Pakistan and identification of five novel mutations : Ff02 (2014) (0)
- Clinical features and outcomes of elderly hospitalised patients with chronic obstructive pulmonary disease, heart failure or both (2023) (0)
- Acquired factor XIII deficiency - an under investigated disorder (2010) (0)
- Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants Myocardial Infarction Genetics Consortium * (2009) (0)
- Romeo and Juliet: Revisited (at the time of COVID-19) (2020) (0)
- Corrigendum to ‘External validation of risk scores to predict in-hospital mortality in patients hospitalized due to coronavirus disease 2019’ (2022) (0)
- Recombinant Factor VIII Fc Fusion Protein for First-time Immune Tolerance Induction: Final Results of the verITI-8 Study. (2023) (0)
- A homozygous duplication of the FGG exon 8-intron 8 junction causes congenital afibrinogenemia. Lessons learned from the study of a large consanguineous Turkish family (2021) (0)
- FRI-256-Procoagulant imbalance in chronic hepatitis C and its relationship with cardiovascular and liver damage (2019) (0)
- Play4Physio: Supporting Physical Therapy of Children with Hemophilia (2022) (0)
- Pulmonary tumour thrombotic microangiopathy in a young man: clinical and immunohistochemical characterisation of a rare complication of gastric signet-ring cell carcinoma. (2021) (0)
- Pro-coagulant imbalance in patients with Cushing disease detected by thrombin generation assay is associated with increased levels of neutrophil extracellular trap-related factors (2016) (0)
- Thrombospondin-1 as a Modulator of ADAMTS13 Activity. (2007) (0)
- Prophylaxis with recombinant von Willebrand factor (rVWF) in patients with type 3 von Willebrand disease (VWD): results of a post hoc analysis from a phase 3 trial. (2023) (0)
- Molecular Mapping of the Chloride Binding Site in von Willebrand Factor (VWF): Energetics and Conformational Effects on the ADAMTS-13 Interaction with Wild Type and Type 2B R1306W VWF Forms. (2006) (0)
- A retrospective study on the use of low-molecular-weight heparin for prevention of pregnancy-related recurrent venous thromboembolism and obstetrical complications (2022) (0)
- Coagulation balance and liver damage in non-cirrhotic patients with chronic hepatitis C after eradication by Direct-acting Antiviral Agents (DAAs) (2021) (0)
- Non-Sense-Mediated mRNA Decay in ADAMTS13 Gene Caused by 29 Nucleotide Deletion. (2006) (0)
- Genetic determinants of enhanced von Willebrand factor clearance from plasma. (2023) (0)
- 9th BIC International Conference: Rome (Italy), 15-17 September 2017. (2017) (0)
- either LMAN1 or MCFD2 Combined deficiency of factor V and factor VIII is due to mutations in (2013) (0)
- Brief report Missense or splicing mutation? The case of a fibrinogen B (cid:1) -chain mutation causing severe hypofibrinogenemia (2004) (0)
- Congenital Bleeding: Autosomal Recessive Disorders (2007) (0)
- The Role of ADAMTS13-Specific Circulating Immune Complexes in Prediction of Recurrence of Acquired Thrombotic Thrombocytopenic Purpura (2014) (0)
- Values for ADAMTS-13 Activity, Antigen and Autoantibodies in Normal European Controls. (2009) (0)
- The usefulness of D-dimer as a predictive marker for mortality in patients with COVID-19 hospitalized during the first wave in Italy (2022) (0)
- Correction to: Usefulness of Fibrosis-4 (FIB-4) score and metabolic alterations in the prediction of SARS-CoV-2 severity (2022) (0)
- The role of the Myocyte Enhancer Factor 2A (MEF2A) gene in the pathogenesis of myocardial infarction (2007) (0)
- 55 ISCHEMIC STROKE IN YOUNG ADULTS: GENETIC ANALYSIS OF 60 POLYMORPHISMS IN 17 GENES INVOLVED IN METHIONINE METABOLISM (2008) (0)
- The Prothrombotic Polymorphism Prothrombin G20210A Is an Ancestral Mutation That Arose in Caucasians Approximately 20,000 Years Ago. (2005) (0)
- Combined Factor V and Factor VIII Deficiency in Rare Coagulation Disorders (2014) (0)
- Foreword (2012) (0)
- Two novel homozygous mutations in the fibrinogen genes identified in two Iranian afibrinogenemic patients (2006) (0)
- Increased Plasma Levels of Von Willebrand Factor and Factor VIII (FVIII) During Acute Bacterial Infection Drive a Pro-Hemostatic Imbalance and Herald Severe Outcome in Cirrhosis (2016) (0)
- Rare Coding Single Nucleotide Variants of ADAMTS13 Are Associated with Deep Vein Thrombosis in a Next-Generation Sequencing Association Study (2012) (0)
- 60. FOUR YEARS EXPERIENCE OF PREIMPLANTATION GENETIC TESTING OF FOUR MONOGENIC DISORDERS (CYSTIC FIBROSIS, BETA-THALASSAEMIA, HEMOPHILIA A AND B) (2019) (0)
- Factor VIII/protein C and not ADAMTS13/VWF:Ag ratio is a prognostic risk factor for patients with cirrhosis and low MELD score (2020) (0)
- Caplacizumab induces fast and durable platelet count responses with improved time to complete remission and recurrence-free survival in patients with acquired thrombotic thrombocytopenic purpura (2020) (0)
- Genetic variants at the chromosomal region 2q21.3 underlying inhibitor development in patients with severe haemophilia A (2022) (0)
- NEW INSIGHTS IN ADAMTS13 PHYSIOLOGY BY MEASURING ACTIVITY OVER ANTIGEN RATIO (2007) (0)
- Impact of von Willebrand factor and ADAMTS-13 on the pro-coagulant imbalance of patients with cirrhosis (2017) (0)
- A comparative study in type 2 von Willebrand disease patients using four different platelet-dependent von Willebrand factor assays. (2023) (0)
- Impact of a commercially available DOAC absorbent on two integrated procedures for lupus anticoagulant detection in plasma containing argatroban (2022) (0)
- Natural History of Patients Affected with Thrombotic Thrombocytopenic Purpura: Milan TTP Registry (2016) (0)
- OUTCOMES OF PATIENTS WITH WORSENING ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) DESPITE DAILY THERAPEUTIC PLASMA EXCHANGE IN THE PHASE 3 HERCULES TRIAL (2020) (0)
- Choices of factor VIII products in previously untreated patients with haemophilia A: A global survey (2018) (0)
- Relevance of Chloride Binding to Von Willebrand Factor in Type 2B Von Willebrand Disease Patients. (2008) (0)
- Prediction of Anti-FVIII Inhibitor Persistence By Anti-FVIII IgG Subclasses in Patients with Severe Hemophilia — A in the Sippet Cohort Study (2018) (0)
- Emicizumab Prophylaxis for the Treatment of Infants with Severe Hemophilia A without Factor VIII Inhibitors: Results from the Interim Analysis of the HAVEN 7 Study (2022) (0)
- Acute Kidney Injury in Non-Intensive Care Unit (ICU) Hospitalizations for Coronavirus Disease (COVID-19) (2022) (0)
- Localization and Function of Platelet ADAMTS-13. (2005) (0)
- ISTH Biennial Impact Report: Looking back and looking forward (2022) (0)
- Comparison of von Willebrand factor platelet‐binding activity assays: ELISA overreads type 2B with loss of HMW multimers (2020) (0)
- Liver-related aspects of gene therapy for hemophilia: need for collaborations with hepatologists. (2022) (0)
- A multicenter, real-world experience with recombinant FXIII for the treatment of patients with FXIII deficiency: from pharmacokinetics to clinical practice. The Italian FXIII Study. (2022) (0)
- Analysis of fibrinogen concentrate pharmacokinetics and dosing for bleeds and surgery in adults, adolescents, and children with congenital afibrinogenaemia and hypofibrinogenaemia (2022) (0)
- Prospective Observation on the Use of Von Willebrand Factor (VWF) Concentrates in a Large Cohort of Type 3 Von Willebrand Disease (VWD): Interim (18-months) Analyses on 149 Cases Enrolled into the 3Winters-Ips Project (2018) (0)
- Abstract 4880: The Common Variant Rs9939609 In The FTO Gene Is Associated With Early-onset Myocardial Infarction (2008) (0)
- Genetics of warfarin response. (2008) (0)
- Real‐world data on emicizumab prophylaxis in the Milan cohort (2022) (0)
- Lung Ultrasound Findings and Endothelial Perturbation in a COVID-19 Low-Intensity Care Unit (2022) (0)
- Efficacy and Safety of Fibrinogen Concentrate for On-demand Treatment of Acute Bleeding and for Surgical Prophylaxis in Subjects with Congenital Fibrinogen Deficiency - A Phase 3 Study (2018) (0)
- Worldwide SARS-COV-2 haplotype distribution (2020) (0)
- WHAT DO WE EXPECT FROM THE INTERNATIONAL REGISTRY (2007) (0)
- Recombinant factor XIII A‐subunit in a patient with factor XIII deficiency and recurrent pregnancy loss (2018) (0)
- INTEGRATED EFFICACY RESULTS FROM THE PHASE 2 AND PHASE 3 STUDIES WITH CAPLACIZUMAB IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA (2021) (0)
- Procoagulant imbalance in chronic hepatitis C and its relationship with cardiovascular and liver damage (2019) (0)
- Idelalisib Rapidly Improves Platelets Function in Patients with Chronic Lymphocytic Leukemia (CLL) (2016) (0)
- Patients Informative Booklet on the Women with rare bleeding disorders project (2007) (0)
- Real-World Experience with Emicizumab Prophylaxis in the Milan Cohort: A Single-Center Experience (2021) (0)
- The Thrombospondin-1 N700S Polymorphism Does Not Alter von Willebrand Factor Multimer Size in Patients Suffering an Acute Myocardial Infarction. (2005) (0)
- Novel fibrinogen gamma-chain mutation p.Asp342Asn ( fibrinogen Pisa) associated with hepatic fibrinogen storage disease and hypofibrinogenemia (2013) (0)
- Identification of DEEP Vein Thrombosis GENETIC RISK Variants by NEXT GENERATION Sequencing of Hemostatic Genes (2011) (0)
- A Multicentre Study on 100 Cases with Thrombotic Thrombocytopenic Purpura: The Role of Adamts-13 Activity and Anti-Adamts-13 Antibodies. (2004) (0)
- ADAMTS13 Activity and Autoantibodies Subclasses as Recurrency Risk Predictors In Acquired Thrombotic Thrombocytopenic Purpura (2010) (0)
- Identification of six novel mutations causing coagulation factor V deficiency (2006) (0)
- Ultrasound Detection of Subquadricipital Recess Distension (2022) (0)
- Factor V Leiden Is Associated with Premature Myocardial Infarction. (2008) (0)
- Abstract 2739: The Proprotein Convertase Subtilisin-kexin Type 9 (PCSK9) R46L Variant Is Associated With Reduced Serum Low-density Lipoprotein Cholesterol In The Italian Population (2007) (0)
- Long-Term Safety and Efficacy of Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura (aTTP): The Post-HERCULES Study (2021) (0)
- Prospective Evaluation of Bleeding Incidence in Fibrinogen Deficiency (PRO-RBDD Study) (2016) (0)
- Thrombin Generation Assay During Orthopaedic Surgery In Hemophilia A With and Without Inhibitors: Results From In Vivo Studies (2013) (0)
- The natural mutation ASP173GLY in the catalytic site of the ADAMTS-13 gene causes a severe Upshaw-Schulman syndrome: clinical course, biochemistry and molecular dynamics investigation (2015) (0)
- LONG-TERM OUTCOMES OF PATIENTS TREATED WITH CAPLACIZUMAB FOR IMMUNE-MEDIATED THROMBOTIC THROMBOCYTOPENIC PURPURA (ITTP): THE POST-HERCULES STUDY (2022) (0)
- Introduction and overview. (2018) (0)
- Assessing Sequence Similarity between FVIII-Derived B-Cell Epitopes and Pathogen-Derived B-Cell Epitopes and the Risk of Inhibitor Development in Patients with Severe Hemophilia a (2022) (0)
- Clustering of Bleeding Symptoms in Patients Previously Diagnosed As Type 3 Von Willebrand Disease: Results from a Large Cohort of Type 3 Von Willebrand Disease (the 3Winters-Ips Project) (2018) (0)
- In Vitro Expression Studies And Immunofluorescence Microscopy Analysis Of Two Naturally Occurring Mutations On Factor X (FX) Gene (G94R And D95E) (2005) (0)
- Emicizumab dose up‐titration in case of suboptimal bleeding control in people with haemophilia A (2022) (0)
- Diagnostic relevance of ADAMTS13 activity: evaluation of 28 patients with thrombotic thrombocytopenic purpura - hemolytic uremic syndrome clinical diagnosis. (2013) (0)
- The haemostatic impact of prion reduction in solvent detergent treated plasma (2010) (0)
- The R1306W Type 2B Natural Mutation of Von Willebrand Factor Dramatically Enhances the Multimer Sensitivity to Shear Stress (2012) (0)
- Thromboplastin calibration revisited to look for possible revision of the World Health Organization recommendations. (2022) (0)
- Fitusiran in haemophilia: a breakthrough drug with many unknowns (2023) (0)
- Increasing levels of von Willebrand factor and factor VIII with age in patients affected by von Willebrand disease: REPLY from original authors Biguzzi et al (2021) (0)
- von Willebrand factor neutralizing and non-neutralizing alloantibodies in 213 subjects with type 3 von Willebrand disease enrolled in 3WINTERS-IPS. (2023) (0)
- Efficacy of Caplacizumab in Patients with aTTP in the HERCULES Study According to Baseline Disease Severity (2019) (0)
- Evaluation of an automated platelet-based assay of von Willebrand ristocetin cofactor activity (2010) (0)
- Liver Health in Patients with Hemophilia: Residual Risk Factors of Liver-Related Complications after HCV Clearance (2022) (0)
- Clinical and genetic determinants of the fatty liver–coagulation balance interplay in individuals with metabolic dysfunction (2022) (0)
- Anti-Emicizumab Antibodies Do Not Cross-React with Mim8 in Vitro (2021) (0)
- Congenital afibrinogenemia : two novel fibrinogen gene mutations identified in two patients from Iran (2006) (0)
- Diagnosis and management of patients with von Willebrand's disease in Italy: an Expert Meeting Report. (2018) (0)
- Successful Chemical Synovectomy in a Patient with Acquired von Willebrand Syndrome with Chronic Synovitis Due to Recurrent Knee Hemarthrosis: A Case Report (2022) (0)
- In vitro characterisation of two ADAMTS13 mutants (I143T, Y570C) identified in two patients with congenital thrombotic thrombocytopenic purpura (TTP) (2013) (0)
- ADAMTS-13 Binds Platelets in a Specific, Divalent Cation and Activation Dependent Manner. (2005) (0)
- Women with rare bleeding disorders (2008) (0)
- Von Willebrand disease combined with coagulation defects in Iran. (2021) (0)
- Plasma FXIII LEVEL Variations During Menstrual CYCLE (2013) (0)
- State of the art on clinical trials of gene therapy in haemophilia (2020) (0)
- Performance of a clinical risk prediction model for inhibitor formation in severe haemophilia A (2021) (0)
- Further comments on "High-titre inhibitors in previously untreated patients with severe haemophilia A receiving recombinant or plasma-derived factor VIII: a budget-impact analysis". (2019) (0)
- Molecular characterization of six novel mutations causing factor V deficiency (2008) (0)
- Risk factors for coronary artery disease in young Iranian: results from the Milano-Iran (MIRAN) study (2015) (0)
- Reproductive care in human immunodeficiency virus serodiscordant couples with haemophilia. (2013) (0)
- Profile of Mutations Identified in the 3WINTERS-IPS Project on European & Iranian Patients with Previously Diagnosed Type 3 Von Willebrand Disease. (2018) (0)
- Relationship between CYP2C9 and VKORC1 polymorphisms and anticoagulant dose requirement (2005) (0)
- Back pain: An old cause in a young adult. (2016) (0)
- International databases open the door to improved care for rare bleeding disorders (2015) (0)
- The Prothrombotic Polymorphism Prothrombin G20210A Is an Ancestral Mutation That Arose in Caucasians Approximately 20,000 Years Ago. (2005) (0)
- YNECOLOGY on Willebrand disease and other bleeding isorders in women : Consensus on diagnosis and anagement from an international expert panel (0)
- Diagnostic utility of bleeding assessment tools in congenital fibrinogen deficiencies. (2023) (0)
- Efficacy and safety of fibrinogen concentrate for perioperative prophylaxis of bleeding in adult, adolescent, and pediatric patients with congenital fibrinogen deficiency: FORMA‐02 and FORMA‐04 clinical trials (2022) (0)
- The role of anticoagulation clinics needs to be reassessed to include follow up of patients on direct oral anticoagulants. (2023) (0)
- Air Pollution and Cardiovascular Health in Middle East and North Africa: Many Shadows but Some Light. (2022) (0)
- The Role of ADAMTS13 Activity Levels on Disease Exacerbation or Relapse in Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura: Post Hoc Analysis of the Phase 3 HERCULES and Post-HERCULES Studies (2022) (0)
- High throughput detection of von Willebrand's disease using a new coagulation analyser (2011) (0)
- Prospective stuty on acute thrombotic microangiopathy (TMA) afetr bone marrow transplantation (BMT) : role of ADAMTS 13, WWF : Ag and high molecular weight Von Willebrand factor (HMW:VWF) (2005) (0)
- Efficacy of rFVIIIFc for First-Time Immune Tolerance Induction (ITI) Therapy: Final Results from the Global, Prospective VerITI-8 Study (2021) (0)
- PROSPECTIVE STUDY OF THE IMMUNOLOGICAL MECHANISMS OF IMMUNE TOLERANCE INDUCTION IN HAEMOPHILIA A PATIENTS WITH INHIBITORS (2017) (0)
- Reduced circulating FABP2 in patients with moderate to severe COVID-19 may indicate enterocyte functional change rather than cell death (2022) (0)
- expression of the recombinant protein moderately severe factor V deficiency: molecular characterization by Arg2074Cys missense mutation in the C2 domain of factor V causing (2013) (0)
- Safety and Efficacy of Fibrinogen Concentrate in Congenital Fibrinogen Deficiency: A Post-Marketing Observational Study (2019) (0)
- The Influence of F8 Mutation and Thrombophilic Genetic Markers on Bleeding Phenotype of Patients Affected with Severe Hemophilia A in the SIPPET Cohort (2017) (0)
- Mutational screening of 25 unrelated FV-deficient patients from six countries (2009) (0)
- Clinical experience in treatment of thrombotic thrombocytopenic purpura--hemolytic uremic syndrome with 28 patients. (2013) (0)
- Which Level of Emicizumab Is Necessary for a Good Hemostasis? (2021) (0)
- Efficacy and Safety of Human Fibrinogen Concentrate for the Treatment of Patients with Congenital Fibrinogen Deficiency: Combined Results of the FORMA-02 and FORMA-04 Clinical Trials (2020) (0)
- Willebrand disease. (2012) (0)
- The Proprotein Convertase Subtilisin-Kexin type 9 (PCSK9) R46L variant is associated with reduced serum low-density lipoprotein cholesterol (LDL-C) in the Italian population (2007) (0)
- Rurioctocog Alfa Pegol Use in Immune Tolerance Induction: Interim Results from an Open-Label Multicenter Clinical Trial in Previously Untreated Patients with Severe Hemophilia a (2021) (0)
- Mutations in LMAN1 and MCFD2 may account for all cases of combined deficiency of factor V and factor VIII. (2005) (0)
- Responsiveness of the activated partial thromboplastin time and dilute thrombin time to argatroban: Results of an in vitro study (2020) (0)
- Emicizumab in acquired hemophilia A: pros and cons of a new approach to the prevention and treatment of bleeding. (2023) (0)
- The First Deletion Mutation in the TSP1-6 Repeat Domain of ADAMTS13 Leads to a Secretion Defect. (2005) (0)
- Is umbilical cord blood a reliable source for the evaluation of neonatal hemostasis 1 at birth ? 2 (2020) (0)
- BSHT and UKHCDO Programme, October 2009 (2009) (0)
- The effect of DNA methylation on inhibitor development in haemophilia A patients treated with FVIII concentrates (2023) (0)
- Mild and Moderate Hemophilia A: Neglected Conditions, Still with Unmet Needs (2023) (0)
- Factor V Leiden but not the factor II 20210G>A mutation is a risk factor for premature coronary artery disease: a case-control study in Iran (2023) (0)
- Evaluation of an Automated Platelet Aggregation Method for the Detection of Patients with Congenital or Acquired Platelet Function Defects (2023) (0)
- Procoagulant imbalance in patients with non-cirrhotic chronic hepatitis C (CHC) improves six months after eradication with direct-acting antiviral agents (DAAs) and likely correlates with liver fibrosis (2020) (0)
- Human Fibrinogen Concentrate for Bleeding Prophylaxis During Surgery in Paediatric Patients with Congenital Fibrinogen Deficiency (2021) (0)
- Characterization of productive and unproductive mRNA splicings in F11 : identification of a novel coagulation FXI isoform (2008) (0)
- INHERITED BLEEDING DISORDERS Rare bleeding disorders : diagnosis and treatment (2015) (0)
- Corrigendum to “Chromosome 3 cluster rs11385942 variant links complement activation with severe COVID-19” [J. Autoimmun. 117C (2020) 102595] (2021) (0)
- Efficacy and Pharmacokinetics of a New Fibrinogen Concentrate in Treating Acute Bleeding in Adolescent Patients with Congenital Fibrinogen Deficiency (2018) (0)
- Title : Degradation of two novel congenital TTP ADAMTS 13 mutants by the cell proteasome prevents ADAMTS 13 secretion (2016) (0)
- Development of a Specific Monoclonal Antibody to Detect Male Cells Expressing the RPS4Y1 Protein (2021) (0)
- The journey of gene therapy in haemophilia – putting the patient at the centre of the hub and spoke model (2022) (0)
- Opium As a Risk Factor for Coronary Artery Disease in Young Iranians: Results from the Premature Coronary Artery Disease Milano-Iran (MIran) Study (2019) (0)
- Recurrence and mortality in young women with myocardial infarction or ischaemic stroke: long term follow-up of the RATIO study (2017) (0)
- High-molecular-weight kininogen and the risk of a myocardial infarction and ischemic stroke in young women: the RATIO case-control study (2012) (0)
- Effect of FV-Leiden Mutation and Antiphospholipid Syndrome on Thethrombin GenerationTest. (2004) (0)
- Covid-19 vaccination in patients with immune-mediated thrombotic thrombocytopenic purpura: a single-referral center experience. (2022) (0)
- Hemorrhagic and Thrombotic Adverse Events Associated with Emicizumab and Extended Half-Life FVIII Replacement Drugs in Patients with Hemophilia a: Data from the Eudravigilance Database (2022) (0)
- Safety and efficacy of recombinant Factor IX fusion protein (rIX-FP) in previously untreated patients with haemophilia B (2023) (0)
- Risk of relapse after SARS-CoV-2 vaccine in the Milan cohort of thrombotic thrombocytopenic purpura patients. (2023) (0)
- Safety of caplacizumab in patients without documented severe adamts13 deficiency during the hercules study (2019) (0)
- Complement activation and renal dysfunction in patients with acquired thrombotic thrombocytopenic purpura. (2023) (0)
- Factor VIII Epitope Analysis Using a Random Peptide Phage-Display Library Approach in the Sippet Cohort (2021) (0)
- The dominant p.Thr274Pro mutation in the von Willebrand factor propeptide causes the von Willebrand disease type 1 phenotype in two unrelated patients (2022) (0)
- Prevalence of selected bleeding and thrombotic events in persons with hemophilia versus the general population: A scoping review (2022) (0)
- The role of hypoxia and inflammation in the regulation of iron metabolism and erythropoiesis in COVID‐19: The IRONCOVID study (2022) (0)
- Inherited Bleeding Disorders in Pregnancy: Rare Coagulation Factor Defects (2012) (0)
- Open ADAMTS13 Conformation in Immune-Mediated Thrombotic Thrombocytopenic Purpura Is Induced By Anti-ADAMTS13 Autoantibodies and Corresponds with an Ongoing ADAMTS13 Pathology (2018) (0)
- The Common Variant Rs9939609 In The FTO Gene Is Associated With Early-onset Myocardial Infarction (ABSTRACT). (2008) (0)
- Risk Factors and Manageability of the Mucocutaneous Bleeding Profile Observed in aTTP Patients Treated with Caplacizumab during the Phase III HERCULES Study (2019) (0)
- Safety Results Normalized to Time of Exposure during the Phase 3 HERCULES Study of Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura (2019) (0)
- Increased plasma levels of Von Willebrand factor (VWF) and Factor VIII (FVIII) during acute bacterial infection drive a pro-hemostatic imbalance and herald severe outcome in cirrhosis (2016) (0)
- International Society on Thrombosis and Haemostasis: Present and future (2021) (0)
- Markedly Reduced FVIII Recovery Associated with Anti-FVIII Peg Antibodies after BNT162b2 Sars-Cov-2 Vaccination (2022) (0)
- GENOME SEQUENCING AND ITS IMPACT ON HEMATOLOGY Genetic sequence analysis of inherited bleeding diseases (2013) (0)
- Opium as a risk factor for early-onset coronary artery disease: Results from the Milano-Iran (MIran) study (2023) (0)
- A homozygous is bp insertion in the human factor vu gene results in modification of a calcium binding site and reduced secretion/function (2000) (0)
- Efficacy of Human Fibrinogen Concentrate for on-Demand Treatment of Acute Bleeding and to Prevent Bleeding during and after Surgery in Subjects with Congenital Fibrinogen Deficiency (2016) (0)
- Impact of von Willebrand factor/ADAMTS-13 on the pro-coagulant imbalance detected in cirrhosis (2017) (0)
- Complications of Pregnancy in Women with Thrombotic Thrombocytopenic Purpura (2012) (0)
- Efficacy and Safety of Human Fibrinogen Concentrate in Patients with Congenital Fibrinogen Deficiency: Combined Results of the FORMA-02 and FORMA-04 Clinical Trials (2021) (0)
- Prospective Study of the Immunological Mechanisms of Immune Tolerance Induction in Severe Haemophilia a Patients with Inhibitors: Preliminary Analysis of a Multi-Center Longitudinal Study (2018) (0)
- ADAMTS-13 Binds Platelets through Gpib. (2009) (0)
- Relevance of chloride binding to von Willebrand factor in type 2B von Willebrand disease patients (2010) (0)
- Table of Contents (2016) (0)
- The Role of B and T Lymphocytes in Recurrent Acquired Thrombotic Thrombocytopenic Purpura. (2009) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Flora Peyvandi?
Flora Peyvandi is affiliated with the following schools:
